<em>Education:</em> An introduction to the core data for cefiderocol with reflections for a possible role within UK clinical practice

JAC Antimicrob Resist. 2021 Jun 15;3(Suppl 1):i17. doi: 10.1093/jacamr/dlab053. eCollection 2021 Jun.

ABSTRACT

The video in this section is a copy of a recorded webinar organized by Shionogi to launch cefiderocol to the UK market in September 2020. Dr Andreas Karas presents the key clinical data for this new antibiotic for MDR Gram-negative infections, followed by reflections from Professor Jonathan Edgeworth on the potential use of the new agent in UK clinical practice. Included in the latter is a case study example of a compassionate use case using cefiderocol.

PMID:34223150 | PMC:PMC8251257 | DOI:10.1093/jacamr/dlab053